Nuvation Bio Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
Nuvation Bio Inc. (NUVB) had Debt Securities, Available-for-sale, Unrealized Loss Position of $301.88 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $301.88M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $218.03M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $18.16M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $124.15M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position | Debt Securities, Available-for-sale, Unrealized Loss Position as first filed |
|---|---|---|
| 2026-06-30 | $301.88M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $218.03M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $18.16M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $124.15M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $188.10M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $192.77M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $186.93M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $98.21M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $480.56M 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $383.75M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $287.44M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $543.87M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $549.87M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $333.34M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $466.42M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $527.88M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $544.43M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $526.62M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $523.28M 10-K · filed 2023-03-15 | $445.21M 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |